Our mission is to positively impact patient lives by providing an optimal platform for the innovation of next generation imaging agents, which will improve diagnostic and therapeutic care, leading to better clinical outcomes. With 14 sites covering major markets, we are able to provide you with the dose you need, when you need it.
We currently offer a number of products for your clinical needs.
F18-NaF is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity.
Package Insert: F18-NaF is an approved product with the FDA, we follow 21 CFR Part 212, USP 797, and Board of Pharmacy regulations, and that we have established an effective quality and sterility assurance systems in place. (Download PDF)
18F-FDG is indicated for positron emission tomography (PET) imaging in the following settings:
Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.
Package Insert: F18-Fludeoxyglucose is an approved product with the FDA, we follow 21 CFR Part 212, USP 797, and Board of Pharmacy regulations, and that we have established an effective quality and sterility assurance systems in place. (Download PDF)
N13-Ammonia is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
Package Insert: N13-Ammonia is an approved product with the FDA, we follow 21 CFR Part 212, USP 797, and Board of Pharmacy regulations, and that we have established an effective quality and sterility assurance systems in place. (Download PDF)
Neuraceq™ is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.
Package Insert: (Download PDF)
2019 Online Learning Series
SOFIE offers a number of educational offerings with the latest information on research trends in nuclear medicine. Be sure to register and join these informative sessions focused on the evidence-based utilization of advanced imaging to improve patient care. A select number of the Online Learning Series webinars have been accredited through recognized programs for technologists to receive CEH.
Looking for more education on PET Imaging? PETLinQ IQ, SOFIE’s PET education web portal, is provided to all customers. Featuring regularly updated pertinent scientific articles, case studies, referrer guides, sample flowcharts, and additional presentations, the IQ Learning Center provides information to provide better service to your patients and referring physicians. We also offer online courses eligible for technologist CE credit.